XAMSBAI
Market cap49mUSD
Dec 20, Last price
0.38EUR
1D
-3.85%
1Q
-51.80%
IPO
-96.21%
Name
BenevolentAI SA
Chart & Performance
P/E
—
P/S
5.42
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
-5.55%
Rev. gr., 5y
1.44%
Revenues
7m
-30.58%
Net income
-63m
L-61.38%
CFO
-57m
L-25.73%
Profile
BenevolentAI S.A. operates as a clinical-stage AI-enabled drug discovery and development company. Its BenevolentAI platform powers in-house drug pipeline of drug programs. The company's therapeutic areas, include atopic dermatitis, ulcerative colitis, amyotrophic lateral sclerosis, glioblastoma multiforme, inflammatory bowel disease, antiviral, oncology, parkinson's disease, nonalcoholic steatohepatitis, fibrosis, inflammation, chronic kidney disease, and idiopathic pulmonary fibrosis. It has a collaboration with AstraZeneca to enhance understanding of complex disease biology and identify new targets. The company was founded in 2013 and is headquartered in London, United Kingdom.
Valuation
Title GBP in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | |
| Income | ||||||
Revenues | 7,331 -30.58% | 10,560 128.32% | 4,625 -33.04% | |||
Cost of revenue | 83,186 | 97,079 | 71,736 | |||
Unusual Expense (Income) | ||||||
NOPBT | (75,855) | (86,519) | (67,111) | |||
NOPBT Margin | ||||||
Operating Taxes | (9,333) | (15,924) | (14,059) | |||
Tax Rate | ||||||
NOPAT | (66,522) | (70,595) | (53,052) | |||
Net income | (63,317) -61.38% | (163,928) 89.55% | (86,484) 56.21% | |||
Dividends | ||||||
Dividend yield | ||||||
Proceeds from repurchase of equity | 136,680 | 7,038 | ||||
BB yield | -35.79% | |||||
| Debt | ||||||
Debt current | 925 | 1,665 | 1,593 | |||
Long-term debt | 8,571 | 13,041 | 15,995 | |||
Deferred revenue | ||||||
Other long-term liabilities | 700 | 626 | 251 | |||
Net debt | (26,981) | (73,736) | (22,965) | |||
| Cash flow | ||||||
Cash from operating activities | (57,124) | (76,911) | (48,904) | |||
CAPEX | (1,105) | (1,158) | (925) | |||
Cash from investing activities | 7,882 | (41,354) | (866) | |||
Cash from financing activities | (2,091) | 162,978 | 5,035 | |||
FCF | (96,529) | (69,071) | (51,037) | |||
| Balance | ||||||
Cash | 36,477 | 88,442 | 40,553 | |||
Long term investments | ||||||
Excess cash | 36,110 | 87,914 | 40,322 | |||
Stockholders' equity | (519,305) | (455,991) | (270,758) | |||
Invested Capital | 619,024 | 617,005 | 342,071 | |||
ROIC | ||||||
ROCE | ||||||
| EV | ||||||
Common stock shares outstanding | 109,110 | 109,110 | 145,126 | |||
Price | 1.08 -69.14% | 3.50 | ||||
Market cap | 117,839 -69.14% | 381,885 | ||||
EV | 90,858 | 308,149 | ||||
EBITDA | (72,975) | (83,463) | (53,468) | |||
EV/EBITDA | ||||||
Interest | 326 | 497 | 448 | |||
Interest/NOPBT | ||||||